183 related articles for article (PubMed ID: 6192858)
1. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.
Talpaz M; McCredie KB; Mavligit GM; Gutterman JU
Blood; 1983 Sep; 62(3):689-92. PubMed ID: 6192858
[TBL] [Abstract][Full Text] [Related]
2. Chronic myelogenous leukaemia: haematological remissions with alpha interferon.
Talpaz M; McCredie K; Kantarjian H; Trujillo J; Keating M; Gutterman J
Br J Haematol; 1986 Sep; 64(1):87-95. PubMed ID: 3463363
[TBL] [Abstract][Full Text] [Related]
3. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.
Talpaz M; Kantarjian HM; McCredie K; Trujillo JM; Keating MJ; Gutterman JU
N Engl J Med; 1986 Apr; 314(17):1065-9. PubMed ID: 3457264
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN alpha) therapy.
Maxwell BL; Talpaz M; Gutterman JU
Int J Cancer; 1985 Jul; 36(1):23-8. PubMed ID: 3160669
[TBL] [Abstract][Full Text] [Related]
5. Clinical investigation of human alpha interferon in chronic myelogenous leukemia.
Talpaz M; Kantarjian HM; McCredie KB; Keating MJ; Trujillo J; Gutterman J
Blood; 1987 May; 69(5):1280-8. PubMed ID: 3471281
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b.
Niederle N; Kloke O; May D; Becher R; Osieka R; Schmidt CG
Invest New Drugs; 1987; 5 Suppl():S19-25. PubMed ID: 3474219
[TBL] [Abstract][Full Text] [Related]
7. Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leucocyte interferon.
Talpaz M; Trujillo JM; Hittelman WN; Keating MJ; Gutterman JU
Br J Haematol; 1985 Aug; 60(4):619-24. PubMed ID: 3861194
[TBL] [Abstract][Full Text] [Related]
8. [Clinical investigation of interferons in the preleukemic state (CML and MDS)].
Koyama S
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1191-7. PubMed ID: 3132893
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human interferon-alpha induced cytoreduction in chronic myelogenous leukemia. Results of a multicenter study.
Werter M; de Witte R; Janssen J; de Pauw B; Haanen C
Blut; 1988 May; 56(5):209-12. PubMed ID: 3285912
[TBL] [Abstract][Full Text] [Related]
10. Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients.
Talpaz M; Spitzer G; Hittelman W; Kantarjian H; Gutterman J
Exp Hematol; 1986 Aug; 14(7):668-71. PubMed ID: 3460811
[TBL] [Abstract][Full Text] [Related]
11. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2',5'-oligoadenylate synthetase.
Rosenblum MG; Maxwell BL; Talpaz M; Kelleher PJ; McCredie KB; Gutterman JU
Cancer Res; 1986 Sep; 46(9):4848-52. PubMed ID: 2942242
[TBL] [Abstract][Full Text] [Related]
12. [alpha 2-interferon: preliminary treatment results in chronic myeloid leukemia].
Niederle N; Kloke O; Doberauer C; Becher R; Beelen DW; Schmidt CG
Dtsch Med Wochenschr; 1986 May; 111(20):767-72. PubMed ID: 3516621
[TBL] [Abstract][Full Text] [Related]
13. Interferon alfa-2b in the treatment of chronic myelogenous leukemia.
Niederle N; Kloke O; Osieka R; Wandl U; Opalka B; Schmidt CG
Semin Oncol; 1987 Jun; 14(2 Suppl 2):29-35. PubMed ID: 3473689
[TBL] [Abstract][Full Text] [Related]
14. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.
Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inverardi D; Bernasconi P; Mancini M; Donti E; Grignani F
Blood; 1988 Aug; 72(2):642-7. PubMed ID: 3165298
[TBL] [Abstract][Full Text] [Related]
15. The activity of alpha interferons in chronic myelogenous leukemia.
Talpaz M
Am J Med Sci; 1988 Aug; 296(2):95-7. PubMed ID: 3165249
[No Abstract] [Full Text] [Related]
16. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
17. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia.
Talpaz M; Mavligit G; Keating M; Walters RS; Gutterman JU
Ann Intern Med; 1983 Dec; 99(6):789-92. PubMed ID: 6580836
[TBL] [Abstract][Full Text] [Related]
18. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
[TBL] [Abstract][Full Text] [Related]
19. [Various aspects and results of therapy with interferon].
Niederle N
Arzneimittelforschung; 1988 Mar; 38(3A):449-53. PubMed ID: 2456071
[TBL] [Abstract][Full Text] [Related]
20. Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.
Aulitzky WE; Peschel C; Desprès D; Aman J; Trautman P; Tilg H; Rudolf G; Hüttmann H; Obermeier J; Herold M
Ann Hematol; 1993 Nov; 67(5):205-11. PubMed ID: 7694661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
